Martin Holst Lange
Martin Holst Lange is the head of development at Novo Nordisk, a global healthcare company known for its innovations in diabetes and obesity treatments. Recently, he announced that the company will explore the potential of its GLP-1 obesity drugs to assist patients struggling with addiction, emphasizing the need for rigorous scientific and regulatory investigation into this promising area.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| United Kingdom | 1 | 7.00 | 0.05% | +0% | 67,886,011 | 31,946 | $2,700,000 | 1,271$ |
| Totals | 1 | 67,886,011 | 31,946 | $2,700,000 | 1,271$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
United Kingdom:
Martin Holst Lange, the Novo Nordisk chief scientific officer, said based on the 'significant unmet need', the company felt it 'had a responsibility to explore semaglutide’s potential, despite a low likelihood of success'.
7
Denmark:
Martin Holst Lange is the research chief at Novo Nordisk who commented on the expected approval for oral weight loss medication.
8
Slovenia:
Martin Holst Lange, the head of research and development at Novo Nordisk, stated that they want to gather evidence on the effects of drugs for common ailments affecting patients' daily lives.
7
United States:
Martin Holst Lange, executive vice president and head of development at Novo Nordisk, previously said in a statement sent to Fox News Digital.
7
Ireland:
Martin Holst Lange, head of development at Novo Nordisk, discussed exploring how obesity drugs can help patients with addiction.
7